University College London Hospitals NHS Foundation Trust, IgniteData and AstraZeneca have successfully gone live in non-production (a mirror image of the live health record with synthetic non-sensitive patient data) testing with IgniteData’s HL7 FHIR enabled clinical trial data transfer platform, Archer. Testing will be conducted on UCLH’s Epic non-production EHR, before going live during Q4 2021 to automate the transfer of data into AstraZeneca’s Medidata Rave for an oncology study.
During 2022, IgniteData will collaborate with AstraZeneca to scale the standardized technology to other NHS and European hospitals. Archer is supervised by the investigator, meaning they maintain full control of which data leaves the hospital and no sensitive data is retained by Archer.
The project does not involve any new sharing of data, beyond the planned data sharing that will occur in the oncology research study. The work with Archer aims to improve the way in which data is transferred between systems.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.